Dietary intakes of flavan-3-ols and cardiometabolic health: systematic review and meta-analysis of randomized trials and prospective cohort studies
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although available data suggest that some dietary flavan-3-ol sources reduce cardiometabolic risk, to our knowledge no review has systematically synthesized their specific contribution. OBJECTIVE: We aimed to examine, for the first time, if there is consistent evidence that higher flavan-3-ol intake, irrespective of dietary source, reduces cardiometabolic risk. METHODS: MEDLINE, Cochrane Central, and Commonwealth Agricultural Bureau abstracts were searched for prospective cohorts and randomized controlled trials (RCTs) published from 1946 to March 2019 on flavan-3-ol intake and cardiovascular disease (CVD) risk. Random-effects models meta-analysis was used. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach assessed the strength of evidence. RESULTS: Of 15 prospective cohorts (23 publications), 4 found highest compared with lowest habitual intakes of flavan-3-ols were associated with a 13% reduction in risk of CVD mortality and 2 found a 19% reduction in risk of chronic heart disease (CHD) incidence. Highest compared with lowest habitual intakes of monomers were associated with a reduction in risk of type 2 diabetes mellitus (T2DM) (n = 5) and stroke (n = 4) (10% and 18%, respectively). No association was found for hypertension. Of 156 RCTs, flavan-3-ol intervention resulted in significant improvements in acute/chronic flow-mediated dilation (FMD), systolic (SBP) and diastolic blood pressure (DBP), total cholesterol (TC), LDL and HDL cholesterol, triglycerides (TGs), hemoglobin A1c (HbA1c), and homeostasis model assessment of insulin resistance (HOMA-IR). All analyses, except HbA1c, were associated with moderate/high heterogeneity. When analyses were limited to good methodological quality studies, improvements in TC, HDL cholesterol, SBP, DBP, HOMA-IR, and acute/chronic FMD remained significant. In GRADE evaluations, there was moderate evidence in cohort studies that flavan-3-ol and monomer intakes were associated with reduced risk of CVD mortality, CHD, stroke, and T2DM, whereas RCTs reported improved TC, HDL cholesterol, SBP, and HOMA-IR. CONCLUSIONS: Available evidence supports a beneficial effect of flavan-3-ol intake on cardiometabolic outcomes, but there was considerable heterogeneity in the meta-analysis. Future research should focus on an integrated intake/biomarker approach in cohorts and high-quality dose-response RCTs. This review was registered at www.crd.york.ac.uk/PROSPERO/ as CRD42018035782.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Del Rio, D., Rodriguez-Mateos, A., Spencer, J. P. E., Tognolini, M., Borges, G., & Crozier, A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4581 · Cited by 2,601
Hooper, L., Kroon, P. A., Rimm, E. B., Cohn, J. S., Harvey, I., Le Cornu, K. A., Ryder, J. J., Hall, W. L., & Cassidy, A. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.1.38 · Cited by 1,097
Self-citation(–)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans
Schroeter, H., Heiss, C., Balzer, J., Kleinbongard, P., Keen, C. L., Hollenberg, N. K., Sies, H., Kwik-Uribe, C., Schmitz, H. H., & Kelm, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510168103 · Cited by 1,052
Hooper, L., Kay, C., Abdelhamid, A., Kroon, P. A., Cohn, J. S., Rimm, E. B., & Cassidy, A. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.023457 · Cited by 610 · cited 1×
“Our RCT results concur with 2 previous meta-analyses that only evaluated a limited number of foods and reported beneficial effects on outcomes including HDL cholesterol, blood pressure, HOMAIR, and FMD (7, 50).”
ResultSelf-citationChocolate consumption and cardiometabolic disorders: systematic review and meta-analysis
Buitrago-Lopez, A., Sanderson, J., Johnson, L., Warnakula, S., Wood, A., Di Angelantonio, E., & Franco, O. H. (2011) · BMJ · doi:10.1136/bmj.d4488 · Cited by 252
Shrime, M. G., Bauer, S. R., McDonald, A. C., Chowdhury, N. H., Coltart, C. E. M., & Ding, E. L. (2011) · The Journal of Nutrition · doi:10.3945/jn.111.145482 · Cited by 234
Recommendations for assessing the risk of bias in systematic reviews of health-care interventions
Viswanathan, M., Patnode, C. D., Berkman, N. D., Bass, E. B., Chang, S., Hartling, L., Murad, M. H., Treadwell, J. R., & Kane, R. L. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.12.004 · Cited by 221 · cited 1×
“For prospective cohort studies, we assessed the following domains: risk of selection, performance, attrition, detection, and selective outcome reporting biases (21).”
MethodCurtis, P. J., Sampson, M., Potter, J., Dhatariya, K., Kroon, P. A., & Cassidy, A. (2012) · Diabetes Care · doi:10.2337/dc11-1443 · Cited by 200 · cited 2×
“Only 1 long-term RCT evaluated clinical outcomes: risk of CHD and stroke (48).”
BackgroundSelf-citationTresserra-Rimbau, A., Guasch-Ferré, M., Salas-Salvadó, J., Toledo, E., Corella, D., Castañer, O., Guo, X., Gómez-Gracia, E., Lapetra, J., Arós, F., et al. (2016) · The Journal of Nutrition · doi:10.3945/jn.115.223610 · Cited by 145
Kim, K., Vance, T. M., & Chun, O. K. (2016) · European Journal of Nutrition · doi:10.1007/s00394-015-0942-x · Cited by 125 · cited 1×
“Included cohorts examined a wide range of dosages of flavan-3-ols; the mean daily intake of flavan-3-ols in the United States is <200 mg/d (58), whereas in some cohorts dosages ≤1400 mg/d (36) were observed and total flavan-3-ol dosages in included RCTs ranged from 40 to 1540 mg/d.”
Background
Cited by
Lifestyle interventions for the prevention and treatment of hypertension
Valenzuela, P. L., Carrera-Bastos, P., Gálvez, B. G., Ruiz-Hurtado, G., Ordovas, J. M., Ruilope, L. M., & Lucia, A. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00437-9 · Cited by 354
Sesso, H. D., Manson, J. E., Aragaki, A. K., Rist, P. M., Johnson, L. G., Friedenberg, G., Copeland, T., Clar, A., Mora, S., Moorthy, M. V., et al. (2022) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac055 · Cited by 187
Caloric Restriction Mimetics in Nutrition and Clinical Trials
Hofer, S. J., Davinelli, S., Bergmann, M., Scapagnini, G., & Madeo, F. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.717343 · Cited by 109
Payne, E. R., Aceves-Martins, M., Dubost, J., Greyling, A., & de Roos, B. (2025) · Nutrition Reviews · doi:10.1093/nutrit/nuaf054 · Cited by 19
“11,12 Intake of tea, and its bioactive compounds studied in isolation, has also been causally linked with short-term improvements in cognitive function and certain mood outcomes.”
Metadata
- Authors
- Raman, G., Avendano, E. E., Chen, S., Wang, J., Matson, J., Gayer, B., Novotny, J. A., & Cassidy, A.
- Venue
- The American Journal of Clinical Nutrition
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 110
- Issue
- 5
- Pages
- 1067-1078
- ISSN
- 0002-9165 (ISSN-L)
- OpenAlex
- W2971353076
- Cited by
- 109
- References
- 10
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dietary intakes of flavan-3-ols and cardiometabolic health: systematic review and meta-analysis of randomized trials and prospective cohort studies. https://app.cochat.ai/papers/10.1093/ajcn/nqz178
- The paper
- Raman, G., Avendano, E. E., Chen, S., Wang, J., Matson, J., Gayer, B., Novotny, J. A., & Cassidy, A. (2019). Dietary intakes of flavan-3-ols and cardiometabolic health: systematic review and meta-analysis of randomized trials and prospective cohort studies. The American Journal of Clinical Nutrition. https://doi.org/10.1093/ajcn/nqz178
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.